Diurnal variations in keratometry and refraction with intracorneal ring segments

Full-Ring Intracorneal Implantation in Corneas With Pellucid Marginal Degeneration

BACKGROUND

Keratoconus (KCN) is a progressive, non-inflammatory ectacic disorder characterized by bilateral and asymmetrical conical protrusion of the cornea. MyoRing implantation and Collagen Crosslink (CXL) are two separate effective treatments for all stages of keratoconous. This study wants to show the effect of these treatments combination in patients with moderate and severe keratoconus.

OBJECTIVES

The aim of this study was to report on the visual and refractive outcomes of corneas with pellucid marginal degeneration following MyoRing implantation (DIOPTEX GmbH).

PATIENTS AND METHODS

This study included 15 eyes of 15 patients, with an age range from 22 to 49 years old, and pellucid marginal degeneration. An intrastromal corneal ring (MyoRing) was inserted by the means of mechanical dissection using a PocketMaker microkeratome. The main outcome measures were uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), manifest refraction, and keratometry readings. The mean postoperative follow-up was ten months (range 6 - 12 months).

RESULTS

The mean UDVA (LogMAR) improved significantly from 1.13 ± 0.21 preoperatively to 0.24 ± 0.13 postoperatively (P < 0.001), and the mean CDVA (LogMAR) improved significantly from 0.39 ± 0.12 to 0.19 ± 0.09 (P < 0.001). The mean cylinder of manifest refraction decreased significantly by 4.00 diopter (D) (P < 0.001). The mean spherical equivalent error (SE) decreased significantly from -6.00 ± 3.60 D to -0.70 ± 1.90 D, at the end of the follow-up period. Furthermore, with regards to corneal topography, a significant reduction was observed in keratometric values. The Kmax, Kmin and Kaverage decreased significantly by 5.00, 1.10 and 4.00 D, respectively (P < 0.001).

CONCLUSIONS

MyoRing implantation using the PocketMaker microkeratome appears to provide an effective method for treating pellucid marginal degeneration. Both UDVA and CDVA improved significantly. The corneal steepening and astigmatism were reduced in all subjects after MyoRing implantation.

Diurnal variations in ocular aberrations of human eyes

PURPOSE

To investigate the diurnal variations in ocular wavefront aberrations over two consecutive days in young adult subjects.

MATERIALS AND METHODS

Measurements of both lower-order (sphero-cylindrical refractive powers) and higher-order (third and fourth-order aberration terms) ocular aberrations were collected for 30 young adult subjects at 10 different times over two consecutive days using a Hartmann-Shack aberrometer. Seventeen subjects were myopic and 13 were emmetropic. Five sets of measurements were collected each day at approximately 3 hourly intervals, with the first measurement taken at ∼9 am and the final measurement at ∼9 pm.

RESULTS

Spherical equivalent refraction (p = 0.029) and spherical aberration (p = 0.043) were both found to undergo significant diurnal variation over the two measurement days. The spherical equivalent was typically found to be at a maximum (i.e. most hyperopic) at the morning measurement, with a small myopic shift of 0.37 ± 0.15 D observed over the course of the day. The mean spherical aberration of all subjects (0.038 ± 0.048 μm) was found to be positive during the day and gradually became more negative into the evening, with a mean amplitude of change of 0.036 ± 0.02 μm. None of the other considered sphero-cylindrical refractive power components or higher-order aberrations exhibited significant diurnal variation over the two days of the experiment (p > 0.05). Except for the lower-order astigmatism at 90/180 degree (p = 0.040), there were no significant differences between myopes and emmetropes in the magnitude and timing of the observed diurnal variations (p > 0.05).

CONCLUSIONS

Significant diurnal variations in spherical equivalent and spherical aberration were consistently observed over two consecutive days of measurement. Research and clinical applications requiring precise refractive error and wavefront measurements should take these diurnal changes into account when interpreting wavefront data.

Intrastromal corneal ring segments to correct low myopia in eyes with irregular or abnormal topography including forme fruste keratoconus: 4-year follow-up

PURPOSE

To report the 4-year outcomes after Intacs intrastromal corneal ring segment (ICRS) implantation to correct low myopia in patients with abnormal topography.

SETTING

Instituto de Microcirugia Ocular, Barcelona, Spain.

METHODS

This retrospective consecutive interventional case series included eyes with myopia lower than -4.50 diopters (D) and abnormal topography that excluded excimer laser surgery. Evaluation was performed preoperatively and at yearly intervals up to 4 years postoperatively. The 4-year outcomes measures were uncorrected (UDVA) and corrected (CDVA) distance visual acuities, predictability and stability of refractive correction, the efficacy and safety indices, and complications.

RESULTS

After ICRS implantation, 82.05% of 39 eyes (21 patients) were within +/-1.00 diopter (D) of emmetropia and 46.15% were within +/-0.50 D. Refractive correction improved during the first 6 months and remained stable up to 4 years. The UDVA was 20/40 or better in all eyes and 20/20 or better in 38.46% of eyes. Seven eyes (17.95%) lost 1 line of CDVA, and no eye lost 2 or more lines. No intraoperative complications occurred. The ICRS were exchanged for thicker ICRS in 7 eyes (17.9%) because of undercorrection. One patient requested ICRS removal due to unsatisfactory refractive results.

CONCLUSIONS

The 4-year results indicate that ICRS implantation is effective and safe in the correction of low myopia in patients for whom excimer laser surgery is contraindicated because of abnormal topography, including forme fruste keratoconus. The achieved refractive correction remained stable throughout the follow-up.

FINANCIAL DISCLOSURE

No author has a financial or proprietary interest in any material or method mentioned.

Ferrara intracorneal ring segments for keratoconus

PURPOSE

To assess the outcome of Ferrara intracorneal ring segments for keratoconus.

SETTING

Private practice and university hospital, Porto Alegre, Brazil.

METHODS

In this retrospective noncomparative interventional case series, 51 keratoconus eyes of 47 patients that had Ferrara intracorneal ring segment implantation were reviewed. Uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), central corneal curvature, corneal astigmatism, surface regularity index, surface asymmetry index, and complications were analyzed.

RESULTS

At a mean follow-up of 13.0 months +/- 8.7 (SD), the BSCVA improved in 86.4% of eyes, was unchanged in 1.9%, and worsened in 11.7%. The UCVA improved in 86.4% of eyes, was unchanged in 7.8%, and worsened in 5.8%. The mean spherical equivalent (SE) was reduced from -6.08 +/- 5.01 diopters (D) to -4.55 +/- 5.71 D and the mean refractive astigmatism, from -3.82 +/- 2.13 D to -2.16 +/- 2.07 D. The mean central corneal curvature was reduced from 48.76 +/- 3.97 D to 43.17 +/- 4.79 D. Eyes with central keratoconus had statistically significantly better results than eyes with inferior keratoconus in topographic astigmatism, SE, and refraction cylinder. Penetrating keratoplasty was avoided in 38 eyes (74.5%) during the follow-up. Intracorneal ring segment decentration occurred in 2 eyes (3.9%), segment extrusion in 10 eyes (19.6%), bacterial keratitis in 1 eye (1.9%) with segment extrusion, and a disciform keratitis in 1 eye (1.9%).

CONCLUSION

Implantation of Ferrara intracorneal ring segments in patients with keratoconus was a safe and reversible procedure that led to stable results and avoided or delayed PKP in many cases.

Intrastromal corneal ring segments for low myopia: a report by the American Academy of Ophthalmology

OBJECTIVE

This document describes intrastromal corneal ring segments (Intacs) inserts technology and examines the evidence to answer the key question about whether the treatment is safe and effective in correcting low myopia.

METHODS

A literature search that was conducted in September 2000 retrieved 13 relevant citations, and the reference lists of these articles were consulted for additional citations. Panel members reviewed this information and articles were rated according to the strength of evidence.

RESULTS

Prospective multicenter phase II and III clinical trials (Level II evidence rating) of Intacs inserts for myopia of -1.00 to -3.00 diopters (D), with a maximum of +1.00 D of astigmatism, enrolled a total of 452 subjects, with a total of 454 surgical attempts. The results from phase II and phase III were pooled for much of the analysis. At 1 year, 97% of patients who completed follow-up had 20/40 or better uncorrected visual acuity (UCVA). Seventy-four percent of patients had 20/20 or better UCVA. Ninety-two percent of eyes were within +/-1 D of intended refractive correction, and 69% were within 0.5 D of intended refractive correction. At 3 months, 90% of patients had less than 1.0 D of change from the previous examination performed at 1 month. The ocular complication rate, which was defined as clinically significant events but not resulting in permanent sequelae, was 11% at 12 months. The adverse event rate was 1.1%, defined as a serious event if untreated. Nearly 9% of patients requested to have their inserts removed and a total of 3.8% of patients required a secondary surgical intervention.

CONCLUSIONS

To date, evidence suggests that low myopia (-1 to -3 D) in a well-defined group of patients who have a stable manifest refraction and less than +1.0 D of astigmatism can be treated with Intacs inserts with a reasonable assurance of safety and effectiveness. Additional clinical research is needed to determine the long-term effectiveness of treatment and the comparative safety, effectiveness, and costs with other treatment modalities, including laser-assisted in-situ keratomileusis (LASIK) and photorefractive keratectomy (PRK).

Surgically induced astigmatism after implantation of intacs intrastromal corneal ring segments

PURPOSE

To analyze surgically induced astigmatism (SIA) after implantation of Intacs intrastromal corneal ring segments.

SETTING

Multicenter clinical trials in the United States.

METHODS

Data from 11 investigational sites involved in the Phase II and III trials of Intacs for the United States Food and Drug Administration were retrospectively analyzed. The distribution of Intacs thicknesses implanted in 449 eyes was 0.25 mm in 148 eyes, 0.30 mm in 151 eyes, and 0.35 mm in 150 eyes. Refractive astigmatism was measured by subjective manifest refraction preoperatively and 1 week and 1, 2, 3, 6, 9, and 12 months postoperatively. The mean simple change in astigmatism and the surgically induced refractive change were determined by vector analysis.

RESULTS

Mean induced astigmatism at 12 months was 0.13 diopter (D) +/- 0.52 (SD). Induced astigmatism was more frequently with the rule (44%) than against the rule (26%) or oblique (30%). Maximal mean astigmatism was 0.50 +/- 1.09 D and occurred at 7 days. Mean induced astigmatism increased with segment thickness (0.01 D, 0.17 D, and 0.21 D for the 0.25 mm, 0.30 mm, and 0.35 mm segments, respectively). Mean surgically induced refractive change in cylinder power in all eyes at 12 months by vector analysis was 0.17 D x 92.

CONCLUSION

Mean SIA was not clinically meaningful 12 months after Intacs implantation.

One year results of European Multicenter Study of intrastromal corneal ring segments. Part 2: complications, visual symptoms, and patient satisfaction

PURPOSE

To assess intraoperative and postoperative complications, visual symptoms, and patient satisfaction after implantation of intrastromal corneal ring segments (ICRS, KeraVision, Inc.) for the correction of myopia and to demonstrate the reversibility and adjustability of refractive corrections with this method.

SETTING

Twelve European investigational sites.

METHODS

Patients with myopia of -1.0 to -6.0 diopters (D) were assigned to receive 1 of 5 ICRS thicknesses (0.25, 0.30, 0.35, 0.40, or 0.45 mm). Complications and visual symptoms were noted, and patient satisfaction was assessed at each postoperative visit (1 and 7 days and 1, 2, 3, 6, and 12 months). Refractive data were assessed after removal or exchange of the ICRS.

RESULTS

Of 163 eyes of 110 patients enrolled, 159 eyes of 107 patients were implanted with an ICRS (52 patients had bilateral implantation). Intraoperative complications occurred in 2% of eyes (4/163 eyes in 3 patients) that were withdrawn from the study: 3 eyes had anterior surface perforations and 1 had a posterior microperforation into the anterior chamber. Most patients had no visual symptoms at 12 months; symptoms usually occurred rarely or sometimes and were mild in severity. At 12 months, good or excellent patient satisfaction was reported for 94% of eyes. Twelve ICRSs (8%) were removed, mainly because of undercorrection and induced astigmatism, and 2 were exchanged. All eyes were within +/-1.00 D of the preoperative manifest refraction spherical equivalent.

CONCLUSIONS

The ICRS was safe for correction of low to moderate myopia. Severe postoperative visual symptoms were rare, and patient satisfaction was high. The refractive correction was largely reversible.

Diurnal stability of refraction after implantation with intracorneal ring segments

PURPOSE

To investigate diurnal changes in visual acuity and refraction in myopic eyes implanted with intracorneal ring segments (ICRS).

SETTING

University of California San Diego Shiley Eye Center, La Jolla, California, and Emory University Vision Correction Center, Atlanta, Georgia, USA.

METHODS

This prospective study involved 2 groups of patients who had ICRS (Intacs) implantation and a follow-up of at least 6 months. The first group included 102 eyes of 51 bilaterally treated patients; the second group, 32 eyes of 16 unilaterally treated patients. Examinations including visual acuity, manifest refraction, and videokeratography were done in the morning and evening at least 9 hours apart on a single day. Refractive changes were analyzed by power vectors; multivariate statistics were used to determine the significance of change in any component of the spectacle prescription.

RESULTS

In the bilateral treatment group, 97 eyes (95%) were within 1 line of spectacle-corrected visual acuity from morning to evening. The mean change in manifest refraction was -0.14 +0.08 x 4 and in spherical equivalent, -0.10 diopters (D) (sigma = 0.3; range -0.750 to +0.875 D). Ninety-six eyes (94%) had a change in refraction within 0.50 D of spherical equivalent. There was no significant change in corneal power (P =.20). In the unilateral treatment group, there was no significant difference between treated and untreated eyes in changes in spectacle-corrected visual acuity, manifest refraction, or corneal power and toricity (P.05).

CONCLUSION

No clinically significant diurnal variation in visual acuity or manifest refraction was observed after ICRS implantation or in untreated paired eyes. Moreover, the data suggest less diurnal change in visual acuity and refraction after ICRS implantation.